Sign Up Today and Learn More About Huma Therapeutics Stock
Invest in or calculate the value of your shares in Huma Therapeutics or other pre-IPO companies through EquityZen's platform.
Huma Therapeutics Stock (HUTH)
Huma provides a digital health platform used for predictive care and research.
About Huma Therapeutics Stock
Founded
2011
Industries
Software, Artificial Intelligence, Data and Analytics
Huma is a global health technology company that provides a modular platform to support digital 'hospitals at home' across different disease areas. Its platform combines predictive algorithms, digital biomarkers, and real-world data to advance proactive, predictive care and research. The company was founded in 2011 and is headquartered in London, England.
Huma Therapeutics Press Mentions
Stay in the know about the latest news on Huma Therapeutics
Digital health startups raise $3B in Q1 as market faces near-term uncertainty
fiercehealthcare • Apr 08, 2025
Huma acquires eConsult to advance digital healthcare in the UK
thenextweb • Oct 03, 2024
Huma Acquires eConsult
finsmes • Oct 03, 2024
Huma Finance Raises $38M to Drive Expansion into Solana and Stellar’s Soroban
coinspeaker • Sep 18, 2024
Huma Raises $38M in Funding
finsmes • Sep 17, 2024
Huma Therapeutics Management
Leadership team at Huma Therapeutics
Co-founder & CEO
Dan Vahdat
Co-founder and Executive Director
Rich Khatib
Join now and verify your accreditation status to gain access to:
- Huma Therapeutics Current Valuation
- Huma Therapeutics Stock Price
- Huma Therapeutics Management
- Available deals in Huma Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Huma Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Huma Therapeutics Revenue and Financials
- Huma Therapeutics Highlights
- Huma Therapeutics Business Model
- Huma Therapeutics Risk Factors
- Huma Therapeutics Research Report from SACRA Research
Trading Huma Therapeutics Stock
How to invest in Huma Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Huma Therapeutics through EquityZen funds. These investments are made available by existing Huma Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Huma Therapeutics stock?
Shareholders can sell their Huma Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
